CHRONIC PANCREATITIS

CHRONIC PANCREATITIS

At a glance

Domain	Practical point
Definition	Progressive fibro-inflammatory pancreatic condition with irreversible structural injury and leading to both exocrine/endocrine dysfunction.
Etiology	Use TIGAR-O: toxic-metabolic, idiopathic, genetic, autoimmune, recurrent/severe acute pancreatitis, obstructive.
Clinical pattern	Pain (major presentation) and/or maldigestion; later steatorrhea, weight loss, diabetes, nutritional and bone complications.
Diagnosis	CT or MRI/MRCP is first line; EUS and pancreatic function testing are adjuncts when diagnosis remains uncertain.
Exocrine Pancreatic insufficiency	Fecal elastase-1 is the practical initial test; interpret on a formed/semi-solid stool specimen.
PERT	Treat confirmed EPI with enteric-coated PERT during meals; start around 40,000 USP lipase units/meal and titrate to response.
Pain	Multimodal treatment; do not use PERT solely for pain. Treat obstructive disease and consider early multidisciplinary intervention.
Endoscopy	For selected obstructing duct stones/strictures, pseudocysts and biliary obstruction; therapeutic rather than routine diagnostic ERCP.
Surgery	Best long-term option for selected obstructive painful CP when endoscopic drainage is inadequate; procedure depends on duct size/head morphology.
Complications	EPI, diabetes, pseudocyst, duct/biliary stricture, splanchnic thrombosis, bone disease, malnutrition and pancreatic cancer.
Prevention	Complete alcohol abstinence and smoking cessation; address nutrition and the underlying etiology.

Definition and clinical spectrum

Chronic pancreatitis (CP) is a fibro-inflammatory syndrome of the pancreas in genetically, environmentally, and/or otherwise susceptible individuals who develop persistent pathologic responses to pancreatic injury or stress. The process causes progressive fibrosis and destruction of exocrine and endocrine tissue.

Feature	Clinical meaning
Structural injury	Fibrosis, ductal irregularity/strictures, calcification, atrophy and/or ductal dilatation.
Exocrine dysfunction	Progressive loss of digestive enzyme secretion → maldigestion, steatorrhea, weight loss and micronutrient deficiency.
Endocrine dysfunction	Loss of islet mass → pancreatogenic/type 3c diabetes; hypoglycemia can be problematic because glucagon secretion is also impaired.
Pain phenotype	Variable: intermittent or continuous, often post-prandial, with a mismatch between pain severity and physical findings.
Complication phenotype	Pseudocyst, pancreatic duct obstruction, biliary/duodenal obstruction, vascular complications, metabolic bone disease and malignancy.

Pathophysiology — the fibrosis model

Repeated pancreatic injury activates pancreatic stellate cells (PSCs), which shift toward a fibrogenic phenotype.
Cytokines, oxidant stress and growth-factor signalling promote extracellular-matrix production and collagen deposition.
Progressive fibrosis and acinar/islet destruction produce both exocrine and endocrine failure.
Alcohol and smoking are not simply exposures: continued exposure is associated with progression, fibrosis and calcification.

Clinical spectrum

Stage/pattern	Typical presentation
Early CP	Pain may predominate; structural abnormalities can be subtle and no single biomarker reliably confirms early disease.
Established CP	Calcification, ductal changes, atrophy and/or clear exocrine dysfunction become more apparent.
Advanced CP	Steatorrhea, weight loss, fat-soluble vitamin deficiency, diabetes and metabolic bone disease are common.
Complicated CP	Pseudocyst, duct leak/fistula, biliary or duodenal obstruction, splanchnic thrombosis, pseudoaneurysm or suspected malignancy.

Etiology — TIGAR-O

Category	Important causes / clues
T — Toxic-metabolic	Alcohol; tobacco; hypercalcemia; hypertriglyceridemia; chronic renal failure; selected toxic/metabolic states.
I — Idiopathic	Early-onset, late-onset and tropical forms.
G — Genetic	PRSS1, CFTR, SPINK1, CTRC, CASR and other pancreatitis-associated variants.
A — Autoimmune	Type 1 AIP (IgG4-related disease); type 2 AIP/idiopathic duct-centric pancreatitis.
R — Recurrent/severe AP	Recurrent acute pancreatitis; post-necrotic CP.
O — Obstructive	Pancreas divisum; duct tumour/stricture; preampullary duodenal-wall cysts; post-traumatic duct stricture.

Heavy alcohol exposure is a major cause of clinically apparent CP, but alcohol alone does not explain susceptibility in every patient.
Smoking is an independent, dose-dependent risk factor and is associated with progression; cessation is a core treatment.
A meaningful fraction of apparently idiopathic CP may have a genetic contribution, especially in younger patients.
Genetic variants can be primary drivers or disease modifiers; interpret results in clinical context.
Autoimmune pancreatitis is a distinct entity within the chronic pancreatitis spectrum and requires separate diagnostic and treatment logic.

When to think genetic

Young age at onset or recurrent acute pancreatitis without a clear acquired cause.
Family history of pancreatitis or pancreatic cancer.
Recurrent disease with little/no alcohol exposure.
Features suggestive of hereditary pancreatitis or cystic-fibrosis-spectrum disease.

Clinical features

Abdominal pain

Usually upper abdominal/epigastric and may radiate to the back.
May be intermittent with pain-free periods or continuous and disabling.
Eating may worsen pain and lead to food avoidance and weight loss.
Physical findings can be modest despite severe reported pain.
Pain may reflect ductal obstruction, inflammatory mass, pseudocyst or neuropathic/central sensitization mechanisms.

Pain mechanism / association	Clue	Management direction
Obstructive ductal pain	Dilated main duct, dominant stricture, obstructing stone	Endoscopic decompression in selected patients; surgical drainage/resection when indicated.
Local complication	Pseudocyst, biliary/duodenal obstruction	Treat the complication.
Neuropathic/central pain	Persistent pain despite adequate structural treatment	Multimodal analgesia, neuromodulator and multidisciplinary pain care.
Cancer-related pain	New/progressive pain with weight loss, jaundice or new ductal changes	Prompt cross-sectional imaging ± EUS/tissue diagnosis.

Exocrine insufficiency — recognize the syndrome

Steatorrhea: bulky, greasy, difficult-to-flush stools ± diarrhea.
Weight loss, bloating, excessive flatulence and malnutrition.
Fat-soluble vitamin deficiency; micronutrient deficiency may occur.
Bone disease is common and clinically important.

Endocrine insufficiency

Pancreatogenic/type 3c diabetes results from loss of endocrine tissue.
Insulin deficiency coexists with impaired glucagon secretion, making hypoglycemia an important concern during treatment.
DKA and classic microvascular complications are less characteristic than in type 1/type 2 diabetes, but glycemic monitoring remains essential.

Red flags for malignancy

New or rapidly worsening pain after a period of stable disease.
Unexplained weight loss, jaundice or new cholestatic biochemistry.
New ductal obstruction/double-duct appearance or a pancreatic mass.
Abrupt change in the clinical course, particularly in older patients.

Diagnosis

There is no single serum biomarker that reliably establishes chronic pancreatitis, particularly in early disease. Diagnosis is clinicoradiologic and should integrate risk factors, symptoms, structural imaging and evidence of pancreatic dysfunction.

Step	What to do	Why
1. Clinical probability	History of alcohol/tobacco, recurrent AP, family history, autoimmune disease, surgery/trauma and obstructive symptoms.	Sets pre-test probability and directs etiologic testing.
2. Cross-sectional imaging	CT or MRI/MRCP as first-line structural tests.	Looks for calcification, atrophy, ductal dilatation/stricture, stones, pseudocyst and mass.
3. EUS if needed	Use when cross-sectional imaging is inconclusive or early CP is suspected.	High-resolution parenchymal/duct assessment; can evaluate malignancy and obtain tissue when indicated.
4. Functional testing	Fecal elastase for suspected EPI; direct pancreatic function testing in selected specialist settings.	Defines exocrine dysfunction rather than replacing structural diagnosis.
5. Reconcile diagnosis	Integrate imaging + symptoms + risk factors + function.	Avoid diagnosing CP from isolated nonspecific EUS or enzyme abnormalities.

Laboratory profile

Test	Typical role	Important limitation
Amylase/lipase	May be normal or only modestly abnormal in CP.	Normal values do not exclude CP; serial levels are not a disease-monitoring tool.
Liver tests	Detect cholestasis from distal CBD obstruction/stricture.	Abnormality is a complication clue, not diagnostic of CP.
Glucose/HbA1c	Screens for pancreatogenic diabetes.	Type 3c diabetes may evolve gradually.
CBC/albumin/weight	Assesses nutritional impact and chronic disease burden.	Nonspecific.
Fat-soluble vitamins, zinc, magnesium, calcium, vitamin D	Assesses malnutrition and bone risk.	Interpret with dietary intake and replacement history.

Classic imaging features

Pancreatic calcifications — especially ductal/parenchymal calcification in advanced disease.
Main pancreatic duct dilatation and irregularity.
Ductal stones and dominant strictures.
Parenchymal atrophy.
Pseudocyst or other local complication.
Biliary duct dilatation or a pancreatic mass should trigger a malignancy/obstruction assessment.

Imaging strategy

Modality	Best use	Key points
CT abdomen	First-line structural assessment; complications and calcification.	Shows calcification, atrophy, ductal dilatation, pseudocyst and masses; excellent overview.
MRI/MRCP	Ductal anatomy, cystic lesions, selected early/uncertain disease.	Secretin-enhanced MRCP can improve ductal evaluation in selected patients.
EUS	Early/uncertain CP; parenchymal/ductal detail; mass evaluation.	Useful when CT/MRI are inconclusive; can perform FNA/FNB when a lesion requires tissue diagnosis.
ERCP	Therapeutic duct/biliary intervention.	Avoid routine diagnostic ERCP because of procedural risk; use after non-invasive imaging identifies a target.
Plain radiograph	Advanced calcific disease in selected settings.	Diffuse pancreatic calcification is a strong clue to established CP.

CT: what you are looking for

Finding	Interpretation
Parenchymal calcification	Established chronic structural injury; diffuse calcification is highly characteristic.
Main duct dilatation	Suggests downstream obstruction or ductal structural disease.
Duct stone	May be a treatable cause of obstructive pain.
Atrophy	Advanced parenchymal loss.
Pseudocyst	Complication; management depends on symptoms, complications and duct anatomy.
Mass/double-duct pattern	Consider pancreatic adenocarcinoma or another obstructing lesion; proceed to appropriate tissue/imaging evaluation.

ERCP: the modern role

ERCP is primarily therapeutic in chronic pancreatitis: duct decompression, stone extraction, pancreatic duct stenting, and selected biliary interventions.
Diagnostic duct assessment is generally better performed with CT/MRI/MRCP/EUS first.
When malignancy is suspected, EUS-guided tissue acquisition is often preferred for a pancreatic mass; ERCP can provide tissue from selected ampullary/distal biliary lesions.

EUS and Rosemont-style assessment

Harrison lists nine EUS abnormalities in chronic pancreatitis. The presence of multiple concordant features is much more persuasive than an isolated nonspecific finding, especially because smoking, diabetes and normal aging can produce some EUS abnormalities.

Nine EUS features checklist

Ductal features	Parenchymal features
1.Pancreatic duct stones	1. Echogenic strands
2. Hyperechoic main duct margins	2. Echogenic foci
3.Main duct irregularity	3. Lobular contour
4.Main duct dilatation	4. Cysts
5.Visible side branches

How to use EUS clinically

Use EUS when CT/MRI do not establish the diagnosis but clinical suspicion remains significant.
Use EUS to investigate a pancreatic mass or suspected malignancy and to obtain FNA/FNB when indicated.
Interpret EUS in context: isolated minor features are not sufficient to label early CP.
The 2020 international EUS consensus notes that ≥5 EUS criteria strongly supports CP and ≤2 strongly argues against it, while acknowledging limitations in early disease.

Tests of exocrine pancreatic function

Type	Test	What it measures	Clinical role
Direct	Secretin stimulation test	Pancreatic fluid/bicarbonate response to secretin.	Most sensitive direct functional test; specialist/research use.
Direct	CCK stimulation test	Pancreatic enzyme secretion after CCK stimulation.	Measures enzyme output; limited routine availability.
Direct	Endoscopic pancreatic function test (ePFT)	Pancreatic juice collected endoscopically after secretin.	Less invasive than duodenal intubation; specialist use.
Indirect	Fecal elastase-1	Stool pancreatic elastase activity.	Most practical initial test for suspected EPI.
Indirect	72-h fecal fat	Quantitative fat malabsorption.	Accurate but cumbersome; rarely needed routinely.
Indirect	Serum trypsinogen	Circulating pancreatic enzyme precursor.	Low levels support advanced exocrine dysfunction; limited sensitivity.
Indirect	Breath tests	Digestion of labelled substrate.	Non-invasive; limited availability.

Fecal elastase-1 — practical interpretation

FE-1 result	Interpretation
>200 μg/g	Generally normal.
100–200 μg/g	Indeterminate / mild–moderate EPI; interpret with clinical context.
<100 μg/g	Good evidence of EPI; severe EPI is more likely.

Pitfalls

Use a formed or semi-solid stool specimen; watery stool can dilute elastase and create a falsely low result.
FE-1 is a test for exocrine dysfunction, not a standalone test for the structural diagnosis of CP.
Fecal fat testing is rarely required in routine practice.
A therapeutic response to PERT should not be used as the sole diagnostic test for EPI.

Direct secretin test

Secretin stimulates pancreatic ductal secretion; the standard test measures duodenal volume and bicarbonate output.
A maximal bicarbonate concentration below 80 mmol/L is abnormal
An abnormal secretin test indicates reduced ductal secretory function but should be interpreted in clinical context and is not by itself synonymous with established CP.

Exocrine pancreatic insufficiency — treatment

Core principle

PERT is the cornerstone of treatment once clinically meaningful EPI is established. The goal is not simply to reduce stool frequency: successful treatment should improve digestion, weight/nutritional status and micronutrient deficiency.

Step	Practical approach
Start PERT	Current AGA advice: at least 40,000 USP units of lipase with each main meal and approximately half that with snacks.
Timing	Take enzymes during the meal; split the dose across the meal when useful for larger meals.
Titrate	Increase according to meal size/fat content and persistent symptoms or nutritional evidence of inadequate response.
If inadequate response	Check adherence, timing, diagnosis, dose and ongoing alcohol/smoking exposure; consider acid suppression when appropriate, particularly with non-enteric-coated preparations or acid-related inactivation concerns.
Monitor	Weight/BMI, stool symptoms, muscle mass, fat-soluble vitamins and other micronutrients; assess bone health.
Diet	Avoid unnecessary very-low-fat diets; use a nutritionally adequate diet with individualized fat intake and dietitian support when needed.

What counts as treatment success?

Less steatorrhea, bloating and gastrointestinal symptoms.
Weight stabilization or gain and improved muscle mass/function.
Correction or improvement of fat-soluble vitamin and micronutrient deficiency.
Improved quality of life and nutritional status.

Monitoring for malnutrition and bone disease

Monitor	Why
Weight/BMI + muscle mass	Tracks response and protein-calorie malnutrition.
Vitamins A, D, E, K	Fat malabsorption can cause deficiency.
Zinc and selected micronutrients	Deficiency may contribute to systemic manifestations.
Calcium/vitamin D + DEXA	Osteopenia/osteoporosis are common in CP.
Glycemic status	EPI and pancreatic endocrine injury frequently coexist.

PERT is NOT a pain treatment

PERT treats maldigestion/EPI. Do not prescribe pancreatic enzymes solely to treat chronic pancreatic pain.
If a patient reports pain improvement with enzymes, reassess the overall pain phenotype and structural disease rather than assuming an enzyme-mediated analgesic effect.

Pain management

Stepwise approach

Define the pain phenotype: obstructive/ductal, inflammatory/local complication, or neuropathic/central.
Eliminate ongoing drivers: complete alcohol abstinence and smoking cessation.
Use multimodal non-opioid analgesia and consider a neuropathic agent such as pregabalin in selected patients.
Avoid using PERT as routine analgesic therapy.
Consider celiac plexus block in selected refractory cases.
If there is a treatable obstructing lesion, move to endoscopic or surgical decompression rather than escalating analgesics indefinitely.

Medical options

Option	Role	Caution
Paracetamol/NSAID when appropriate	Early analgesic strategy in selected patients.	NSAID toxicity; tailor to renal/GI/CV risk.
Pregabalin / neuropathic agents	Useful in selected patients with neuropathic/central pain phenotype.	Sedation, dizziness and dose adjustment when required.
Antioxidants	May be considered in selected patients; overall benefit is limited/inconsistent.	Not a substitute for structural treatment or lifestyle change.
Opioids	Reserve for refractory pain after multidisciplinary assessment.	Dependence, tolerance, constipation and hyperalgesia risk.
PERT	Treats EPI, not routine pain.	Do not use solely for analgesia.

When pain should trigger imaging/reassessment

New or rapidly progressive pain.
New jaundice, cholestatic liver tests or weight loss.
New ductal dilatation/stricture or a pancreatic mass.
Pain despite adequate management of a known obstructing lesion.

Endoscopic management

Who is a candidate?

Persistent severe pain with a correctable obstructing pancreatic duct lesion.
Dominant duct stricture or obstructing pancreatic duct stone.
Symptomatic/complicated pseudocyst.
Benign biliary stricture causing clinically important obstruction.
Selected pancreatic duct leaks/fistulas.

Problem	Endoscopic options	Key principle
Pancreatic duct stone	ERCP extraction ± pancreatoscopy; ESWL for selected large/impacted stones.	Aim for duct clearance/decompression.
Dominant pancreatic duct stricture	ERCP with pancreatic duct stenting in selected patients.	Treat obstruction; reassess response and need for definitive surgery.
Pseudocyst	EUS-guided transmural drainage or transpapillary drainage in selected anatomy.	Drain when symptomatic/complicated or when otherwise indicated; size alone is not a universal indication.
Benign biliary stricture	Endoscopic biliary stenting in appropriate patients.	Treat clinically significant obstruction; surgery if refractory or anatomy demands it.
Pancreatic duct leak	Transpapillary bridging stent when anatomically feasible.	Bridging the disruption is preferred when possible.

Modern decision point: endoscopy versus surgery

For painful obstructive CP, surgical evaluation should occur early, especially when a durable decompression procedure is feasible.
Endoscopy is appropriate when surgery is contraindicated, declined, or when endoscopic clearance/decompression is likely to be complete.
Repeated unsuccessful endoscopic procedures should not delay definitive surgical assessment.

ESWL — when to remember it

Useful for selected obstructing pancreatic duct stones, particularly when stone size/location makes conventional extraction difficult.
Usually followed by ERCP for fragment extraction when needed.

Surgical management

When surgery is favored

Intractable pain with obstructive disease after appropriate medical/endoscopic management.
Local complications of adjacent organs that require definitive treatment.
Suspicion of malignancy or a lesion that cannot be adequately characterized.
Selected patients with a dilated pancreatic duct where surgical drainage can provide durable decompression.

Operation	Typical setting	Concept
Lateral pancreaticojejunostomy (Puestow)	Dilated main pancreatic duct without dominant head mass.	Longitudinal duct drainage into jejunum.
Frey procedure	Enlarged/inflammatory pancreatic head + obstructed duct.	Coring of pancreatic head + longitudinal pancreaticojejunostomy.
Beger procedure	Selected inflammatory pancreatic-head disease.	Duodenum-preserving pancreatic head resection with drainage.
Pancreaticoduodenectomy (Whipple)	Head-dominant disease with suspicion/confirmed malignancy or selected groove pancreatitis.	Resection of pancreatic head/duodenum with reconstruction.
Distal pancreatectomy	Selected body/tail-dominant focal disease.	Tail/body resection; endocrine/exocrine consequences considered.
Total pancreatectomy ± islet autotransplantation	Highly selected refractory disease.	Major irreversible metabolic consequence; specialist-center decision.

Surgical decision matrix

Morphology	Preferred concept
Dilated duct + no dominant head mass	Drainage procedure such as lateral pancreaticojejunostomy; Frey may also be considered.
Enlarged inflammatory head	Frey/Beger-type head-directed surgery depending on anatomy and expertise.
Suspected malignancy	Oncologic resection pathway; obtain appropriate staging/tissue where indicated.
Duodenal/biliary obstruction refractory to endoscopy	Surgical decompression/resection based on cause and anatomy.

Why surgery should not be delayed indefinitely

Repeated obstruction and inflammation can worsen structural damage and quality of life.
Consensus guidance supports earlier surgery in appropriate obstructive CP when long-term pain control is the goal.

Pancreatogenic diabetes, nutrition and bone disease

Type 3c / pancreatogenic diabetes

Problem	Practical approach
Insulin deficiency	Insulin is commonly required when endocrine failure is established.
Glucagon deficiency	Hypoglycemia may be more difficult to recognize/manage because counter-regulatory glucagon secretion is impaired.
Nutrition	Avoid unnecessary caloric restriction; coordinate carbohydrate intake with enzyme replacement and glucose therapy.
Monitoring	HbA1c and glucose monitoring; individualize targets according to hypoglycemia risk and comorbidity.
Associated EPI	Treat EPI concurrently because maldigestion affects nutritional status and may complicate glycemic variability.

Nutritional management

Use frequent, nutritionally dense meals when appetite is poor.
Do not impose severe fat restriction solely because steatorrhea is present; optimize PERT instead.
Assess protein-calorie intake, weight trajectory and muscle mass.
Replace documented or strongly suspected micronutrient deficiencies.
Dietitian involvement is valuable in advanced EPI, weight loss or difficult diabetes.

Metabolic bone disease

Osteopenia/osteoporosis is common in CP and reflects nutritional deficiency, vitamin D deficiency, inflammation, alcohol/smoking exposure and other factors.
Obtain baseline bone mineral density in patients with EPI/CP at meaningful nutritional risk and repeat according to risk and local guidance.
Ensure adequate calcium/vitamin D intake and treat established osteoporosis according to standard osteoporosis principles.

Practical follow-up bundle

At follow-up	Check
Every visit / periodic	Pain phenotype, alcohol/tobacco exposure, weight/BMI, stool symptoms, adherence to PERT.
Metabolic	Glucose/HbA1c; hypoglycemia episodes if on insulin.
Nutrition	Fat-soluble vitamins, selected micronutrients, albumin/prealbumin only as context—not as isolated nutrition markers.
Bone	Vitamin D and DEXA according to risk.
Structural disease	New jaundice, worsening pain, obstruction, recurrent pseudocyst or malignancy red flags.

Complications of chronic pancreatitis

Category	Complications	Key clinical clue
Local / ductal	Pseudocyst; pancreatic duct stricture/stone; duct disruption; fistula.	Pain, mass, recurrent collections, ascites or obstructive symptoms.
Biliary	Distal CBD stricture, cholestasis/biliary cirrhosis.	Jaundice, raised bilirubin/ALP, duct dilatation.
Duodenal / gastric	Gastric outlet or duodenal obstruction.	Vomiting, early satiety, weight loss.
Vascular	Splenic/portal/SMV thrombosis; gastric varices; pseudoaneurysm; hemosuccus pancreaticus.	GI bleeding, anemia, portal-hypertension findings or sudden pain/bleeding.
Exocrine	EPI, steatorrhea, fat-soluble vitamin deficiency, malnutrition.	Bulky greasy stools, weight loss, deficiencies.
Endocrine	Type 3c diabetes; hypoglycemia risk.	New hyperglycemia or glucose variability.
Skeletal	Osteopenia/osteoporosis.	Fracture risk, low BMD, vitamin D deficiency.
Neoplastic	Pancreatic adenocarcinoma.	New/worsening symptoms, jaundice, mass or ductal obstruction.

Local and vascular complications

Pancreatic pseudocyst

A mature, encapsulated pancreatic fluid collection associated with pancreatitis/duct disruption.
Symptoms/complications drive intervention: pain, infection, bleeding, rupture, gastric/duodenal/biliary obstruction or other clinically significant mass effect.
Size alone is not a universal indication for drainage in modern practice.
EUS-guided drainage is preferred when endoscopic drainage is appropriate; duct anatomy should be assessed when a leak/communication is suspected.

Pancreatic ascites / fistula

Usually reflects pancreatic duct disruption or leakage from a pseudocyst.
Ascitic fluid typically has a markedly elevated amylase concentration.
MRCP and/or ERCP can define duct anatomy and identify a disruption.
When feasible, a transpapillary stent that bridges the disruption can promote closure; refractory cases may require surgery.

Splenic/portal venous thrombosis and gastric varices

Can produce left-sided portal hypertension and gastric varices.
Bleeding may be life-threatening and requires specialist endoscopic/interventional management.

Pseudoaneurysm / hemosuccus pancreaticus

Consider with sudden severe abdominal pain, sentinel bleeding or GI hemorrhage in established CP/pseudocyst.
CT angiography is an important diagnostic study when stable enough; angiographic embolization is a preferred definitive approach when feasible.

Biliary obstruction, duodenal obstruction and malignancy

Biliary stricture

Chronic inflammatory/fibrotic change around the intrapancreatic CBD can produce distal biliary obstruction.
Clinical clues: jaundice, pruritus, cholestatic liver tests and biliary dilatation.
Exclude pancreatic cancer when the clinical course is atypical or a mass/double-duct pattern is present.
Endoscopic biliary therapy is appropriate in selected symptomatic obstruction; surgery is considered when endoscopic treatment fails or when resection is otherwise indicated.

Duodenal obstruction

May result from inflammatory pancreatic-head enlargement, fibrosis or a pseudocyst.
Typical symptoms: vomiting, early satiety, post-prandial fullness and weight loss.
Treat the underlying obstructive lesion; surgical management is often required when fixed obstruction persists.

Pancreatic cancer risk

Point	Clinical meaning
CP is a risk state	CP is associated with increased pancreatic cancer risk, but absolute risk varies by etiology.
Highest-risk phenotypes	Hereditary PRSS1 and tropical pancreatitis carry particularly increased risk in Harrison’s discussion.
Routine population-like surveillance	Not recommended for all sporadic CP solely because CP is present.
Hereditary CP	Specialist surveillance/risk counselling is appropriate because cancer risk is substantially higher.
New change in course	New jaundice, weight loss, pain or ductal obstruction should trigger evaluation rather than being attributed automatically to CP.

Double-duct sign

Concurrent obstruction/dilatation of the pancreatic duct and common bile duct raises concern for a pancreatic head/ampullary obstructing lesion. In a patient with established CP, do not automatically attribute a new double-duct pattern to benign chronic inflammation; evaluate for malignancy.

What NOT to do

Avoid	Why
Do not diagnose CP from pain alone.	Chronic abdominal pain has many causes; structural/functional evidence is needed.
Do not rely on serum amylase/lipase to establish or monitor CP.	Levels may be normal or modestly abnormal and do not reflect chronic structural severity.
Do not use isolated EUS minor features as proof of early CP.	Smoking, diabetes and aging can produce nonspecific EUS changes.
Do not use ERCP as routine diagnostic imaging.	CT/MRI/MRCP/EUS generally provide safer diagnostic assessment.
Do not prescribe PERT solely for pain.	PERT treats EPI; evidence does not support routine analgesic use.
Do not drain every pseudocyst based only on size.	Symptoms, complications, duct anatomy and clinical context determine intervention.
Do not repeatedly perform unsuccessful endoscopic procedures without reassessing surgery.	Durable decompression may require definitive surgery.
Do not overlook smoking.	Smoking independently promotes CP progression.
Do not impose a severe fat-restricted diet in EPI.	Adequate nutrition plus effective PERT is preferred.
Do not label new jaundice/weight loss as “just CP.”	Superimposed malignancy or obstruction must be excluded.

Evidence-based updates

Older teaching	Current refinement
“CP = irreversible disease; nothing changes.”	Diagnosis should aim to identify the pathologic process earlier and manage the syndrome holistically.
Routine diagnostic ERCP	CT/MRI/MRCP/EUS first; ERCP mainly therapeutic.
Enzymes for pancreatic pain	PERT is for EPI; routine analgesic use is not recommended.
Repeated endoscopic procedures before surgery	Surgical evaluation should occur early in operable painful obstructive CP.
PERT doses often written as very low fixed doses	Current AGA advice starts at ≥40,000 USP lipase units/meal and titrates to response.
Pseudocyst drainage by size threshold alone	Symptomatic/complicated lesions are the main indication; size alone is not sufficient in modern guidance.
Routine cancer screening in all CP	No universal surveillance strategy for sporadic CP; hereditary high-risk patients need specialist surveillance/risk management.
Severe fat restriction for steatorrhea	Optimize PERT and nutritional adequacy rather than unnecessarily restricting fat.

Bedside algorithm

If you see…	Think…	Do…
Pain + dilated duct/stone	Obstructive painful CP	Multidisciplinary endoscopic vs surgical decompression.
Steatorrhea/weight loss	EPI	FE-1 + nutritional assessment → PERT.
Jaundice/cholestatic tests	CBD stricture/stone or cancer	CT/MRI/MRCP/EUS → therapeutic ERCP when indicated.
New mass/double-duct pattern	Malignancy until excluded	EUS ± FNA/FNB and staging pathway.
Pain + enlarging cyst	Pseudocyst/collection complication	CT/MRI/MRCP/EUS → drainage if symptomatic/complicated.
GI bleed + CP	Varix/pseudoaneurysm/hemosuccus	Urgent CT angiography/endoscopy/interventional radiology as appropriate.
Diabetes + CP	Type 3c diabetes	Glucose/HbA1c + individualized insulin strategy; monitor hypoglycemia.

References

1. Harrison’s Principles of Internal Medicine. 22nd ed. Chapter 359: Acute and Chronic Pancreatitis.

2. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. 12th ed.

3. Gardner TB, Adler DG, Forsmark CE, Sauer BG, Taylor JR, Whitcomb DC. ACG Clinical Guideline: Chronic Pancreatitis. Am J Gastroenterol. 2020;115(3):322–339.

4. Sheth SG, et al. American Society for Gastrointestinal Endoscopy guideline on the role of endoscopy in the management of chronic pancreatitis. Gastrointest Endosc. 2024.